210 related articles for article (PubMed ID: 25466846)
21. Development of a new laboratory test to evaluate antithrombin resistance in plasma.
Murata M; Takagi A; Suzuki A; Okuyama E; Takagi Y; Ando Y; Kato I; Nakamura Y; Murate T; Matsushita T; Saito H; Kojima T
Thromb Res; 2014 Feb; 133(2):293-8. PubMed ID: 24325876
[TBL] [Abstract][Full Text] [Related]
22. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
Tran TH; Duckert F
Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
[TBL] [Abstract][Full Text] [Related]
23. Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets.
Stevic I; Chan HH; Chander A; Berry LR; Chan AK
Thromb Haemost; 2013 Jun; 109(6):1016-24. PubMed ID: 23494009
[TBL] [Abstract][Full Text] [Related]
24. The role of Arg46 and Arg47 of antithrombin in heparin binding.
Arocas V; Bock SC; Olson ST; Björk I
Biochemistry; 1999 Aug; 38(31):10196-204. PubMed ID: 10433728
[TBL] [Abstract][Full Text] [Related]
25. Homozygous or compound heterozygous qualitative antithrombin III deficiency.
Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):335-7. PubMed ID: 7971256
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of poly(acrylic acid) acceleration of antithrombin inhibition of thrombin: implications for the design of novel heparin mimics.
Monien BH; Cheang KI; Desai UR
J Med Chem; 2005 Aug; 48(16):5360-8. PubMed ID: 16078853
[TBL] [Abstract][Full Text] [Related]
27. [The functional study of antithrombin L99 mutation].
Yu T; Dai J; Ding Q; Fu Q; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):191-6. PubMed ID: 24666482
[TBL] [Abstract][Full Text] [Related]
28. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency.
Luxembourg B; Pavlova A; Geisen C; Spannagl M; Bergmann F; Krause M; Alesci S; Seifried E; Lindhoff-Last E
Thromb Haemost; 2014 Feb; 111(2):249-57. PubMed ID: 24196373
[TBL] [Abstract][Full Text] [Related]
29. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths.
Wagenvoord R; Al Dieri R; van Dedem G; Béguin S; Hemker HC
Thromb Res; 2008; 122(2):237-45. PubMed ID: 18045667
[TBL] [Abstract][Full Text] [Related]
30. Clinical multicenter evaluation of a new FXa-based Antithrombin assay.
Merz M; Böhm-Weigert M; Braun S; Cooper PC; Fischer R; Hickey K; Steffan A; Kemkes-Matthes B; Kitchen S
Int J Lab Hematol; 2011 Oct; 33(5):498-506. PubMed ID: 21535419
[TBL] [Abstract][Full Text] [Related]
31. Allosteric activation of antithrombin critically depends upon hinge region extension.
Langdown J; Johnson DJ; Baglin TP; Huntington JA
J Biol Chem; 2004 Nov; 279(45):47288-97. PubMed ID: 15326167
[TBL] [Abstract][Full Text] [Related]
32. The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity.
Dementiev A; Petitou M; Herbert JM; Gettins PG
Nat Struct Mol Biol; 2004 Sep; 11(9):863-7. PubMed ID: 15311268
[TBL] [Abstract][Full Text] [Related]
33. Adverse effect of heparin in thrombin-antithrombin III interaction.
Marciniak E
Thromb Diath Haemorrh; 1975 Dec; 34(3):748-62. PubMed ID: 1209544
[TBL] [Abstract][Full Text] [Related]
34. Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin.
Rezaie AR; Yang L; Manithody C
Biochemistry; 2004 Mar; 43(10):2898-905. PubMed ID: 15005625
[TBL] [Abstract][Full Text] [Related]
35. Experimental proof for the structure of a thrombin-inhibiting heparin molecule.
Petitou M; Imberty A; Duchaussoy P; Driguez PA; Ceccato ML; Gourvenec F; Sizun P; Hérault JP; Pérez S; Herbert JM
Chemistry; 2001; 7(4):858-73. PubMed ID: 11288878
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex.
Stevic I; Berry LR; Chan AK
J Biochem; 2012 Aug; 152(2):139-48. PubMed ID: 22518847
[TBL] [Abstract][Full Text] [Related]
37. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency.
van Boven HH; Reitsma PH; Rosendaal FR; Bayston TA; Chowdhury V; Bauer KA; Scharrer I; Conard J; Lane DA
Thromb Haemost; 1996 Mar; 75(3):417-21. PubMed ID: 8701400
[TBL] [Abstract][Full Text] [Related]
38. Homozygous variant of antithrombin III: AT III Fontainebleau.
Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
[TBL] [Abstract][Full Text] [Related]
39. Assessment of interference by heparin cofactor II in the DuPont aca antithrombin-III assay.
Hortin GL; Tollefsen DM; Santoro SA
Am J Clin Pathol; 1988 Apr; 89(4):515-7. PubMed ID: 3354504
[TBL] [Abstract][Full Text] [Related]
40. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
